title: Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma.
abstract: OBJECTIVE
  (90)Yttrium-ibritumomab-tiuxetan (Zevalin) is an effective treatment for relapsed or refractory low-grade, follicular, or transformed B-cell NHL. The purpose of this study is to assess whether tissue and cellular localization of (90)Y-ibritumomab-tiuxetan determined by autoradiography and radioactivity localized to tumor tissue might enhance our understanding of the mechanism of action of radioimmunotherapy.
  
  
  METHODS
  Eight eligible patients had CD20+ NHL, a bulky peripheral lymph node, and were scheduled for (90)Y-ibritumomab-tiuxetan treatment. 2-Deoxy-2-[F-18]fluoro-D: -glucose-positron emission tomography/computed tomography (FDG-PET/CT) was performed prior to treatment and at 12 weeks after therapy for assessment of response. Bone marrow, lymph node, and blood samples were collected 114 +/- 3 h after 14.8 MBq/kg (90)Y-ibritumomab-tiuxetan and processed for histology, scintillation counting, and microscopic autoradiography.
  
  
  RESULTS
  Pericellular membrane localization of (90)Y-ibritumomab-tiuxetan to lymphoma cells was observed by autoradiography in the involved areas of lymph node with absence of significant localization in histologically normal sections of bone marrow. Pericellular radioactivity and the highest quantitative radioactivity were observed in lymph node samples of responding patients.
  
  
  CONCLUSIONS
  (90)Y-ibritumomab-tiuxetan localizes to the surface membrane of CD20+ lymphoma cells in affected lymph nodes. The patients with the highest quantitative concentration of radioactivity to the lymph node as determined by scintillation counting were observed to have a clinical and FDG-PET/CT response.
authors.affiliation: University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute and UPMC Cancer Centers, PA 15232, USA. jacobssa@upmc.edu
authors.forename: S A
authors.initials: SA
authors.lastname: Jacobs
authors.forename: A M
authors.initials: AM
authors.lastname: Harrison
authors.forename: S H
authors.initials: SH
authors.lastname: Swerdlow
authors.forename: K A
authors.initials: KA
authors.lastname: Foon
authors.forename: N
authors.initials: N
authors.lastname: Avril
authors.forename: N
authors.initials: N
authors.lastname: Vidnovic
authors.forename: J
authors.initials: J
authors.lastname: Joyce
authors.forename: N
authors.initials: N
authors.lastname: DeMonaco
authors.forename: K S
authors.initials: KS
authors.lastname: McCarty
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology; D001345:Autoradiography; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000532:radiotherapy; D008224:Lymphoma, Follicular / Q000532:radiotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000532:radiotherapy; D020522:Lymphoma, Mantle-Cell / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000532:radiotherapy*; D008875:Middle Aged; D016499:Radioimmunotherapy / Q000379:methods*; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan
references.citation: Semin Oncol. 1999 Oct;26(5 Suppl 14):58-65
references.pmid: 10561019
references.citation: J Clin Oncol. 2001 Oct 1;19(19):3918-28
references.pmid: 11579112
references.citation: J Nucl Med. 2002 Nov;43(11):1507-29
references.pmid: 12411555
references.citation: Semin Oncol. 2005 Feb;32(1 Suppl 1):S27-35
references.pmid: 15786023
references.citation: J Clin Oncol. 2002 Aug 1;20(15):3262-9
references.pmid: 12149300
references.citation: J Clin Oncol. 2005 Jul 20;23(21):4652-61
references.pmid: 15837965
references.citation: Blood. 2001 Sep 1;98(5):1352-7
references.pmid: 11520782
references.citation: J Radiat Res. 2005 Jun;46(2):241-8
references.pmid: 15988143
references.citation: J Cell Biol. 1993 Jun;121(5):1121-32
references.pmid: 7684739
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1263-70
references.pmid: 12663713
references.citation: Blood. 2002 Jun 15;99(12):4336-42
references.pmid: 12036859
references.citation: Blood. 2000 Jun 15;95(12):3900-8
references.pmid: 10845926
references.citation: J Clin Oncol. 1999 Dec;17(12):3793-803
references.pmid: 10577851
references.citation: Blood. 2004 Jun 15;103(12):4429-31
references.pmid: 15016644
references.citation: J Clin Oncol. 1999 Apr;17(4):1244
references.pmid: 10561185
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7565-73
references.pmid: 16186600
references.citation: Clin Cancer Res. 2000 Jan;6(1):317-8
references.pmid: 10656464
references.citation: Nat Med. 2001 Sep;7(9):987-9
references.pmid: 11533692
references.citation: J Clin Oncol. 2001 Jan 15;19(2):414-9
references.pmid: 11208833
references.citation: J Clin Oncol. 2005 Feb 1;23(4):712-9
references.pmid: 15613695
references.citation: Blood. 2004 Nov 1;104(9):2635-42
references.pmid: 15226177
references.citation: Blood. 1994 Jan 15;83(2):435-45
references.pmid: 7506951
references.citation: Cell Immunol. 2000 Aug 25;204(1):55-63
references.pmid: 11006018
references.citation: J Clin Oncol. 2002 May 15;20(10):2453-63
references.pmid: 12011122
references.citation: Cancer Biother Radiopharm. 2005 Apr;20(2):185-8
references.pmid: 15869453
references.citation: Clin Cancer Res. 1999 Mar;5(3):611-5
references.pmid: 10100713
references.citation: Cancer Res. 1992 Oct 1;52(19):5144-53
references.pmid: 1327501
references.citation: Blood. 1984 Jun;63(6):1424-33
references.pmid: 6609729
references.citation: Immunol Today. 1994 Sep;15(9):450-4
references.pmid: 7524522
references.citation: Blood. 2004 Oct 15;104(8):2269-71
references.pmid: 15166030
references.citation: Blood. 1999 Jul 15;94(2):429-33
references.pmid: 10397709
references.citation: Blood. 2003 Feb 1;101(3):949-54
references.pmid: 12393572
references.citation: Blood. 2006 Sep 15;108(6):1975-8
references.pmid: 16705086
references.citation: Blood. 2001 Dec 1;98(12):3383-9
references.pmid: 11719378
references.citation: Cancer Res. 2007 Feb 1;67(3):1270-81
references.pmid: 17283164
references.citation: Curr Opin Oncol. 1999 Sep;11(5):375-80
references.pmid: 10505774